LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

LLY

1,142.47

+1.34%↑

JNJ

234.86

+2.94%↑

ABBV

229.14

+2.6%↑

UNH

400.05

+1.05%↑

MRK

121.94

+1.97%↑

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Ouvert

16.95 -1.74

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.91

Max

18.18

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+26.14% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	121M 2.4B
Ouverture précédente	18.69
Clôture précédente	16.95

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 juin 2026, 21:51 UTC

Principaux Mouvements du Marché

Merlin Shares Rally After Defense Department's Design Review Wraps

4 juin 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 juin 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 juin 2026, 23:42 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 juin 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

Energy Resources of Australia to Enter Trading Halt

4 juin 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 juin 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 juin 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 juin 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 20:44 UTC

Acquisitions, Fusions, Rachats

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 juin 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 juin 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 juin 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 juin 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 juin 2026, 18:47 UTC

Acquisitions, Fusions, Rachats

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 juin 2026, 18:38 UTC

Résultats

Money Quote: Tech Weakness in Context -- WSJ

4 juin 2026, 18:24 UTC

Résultats

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 juin 2026, 16:58 UTC

Résultats

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 juin 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 juin 2026, 16:38 UTC

Résultats

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 juin 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 juin 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 juin 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 juin 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

26.14% hausse

Prévisions sur 12 Mois

Moyen 20.17 USD 26.14%

Haut 22 USD

Bas 18 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.